- 24/7 Wall St.•45 minutes ago
Shares of Array BioPharma saw a handy gain in Tuesdays session following the announcement of mid-stage results from its cardiomyopathy trial.
- PR Newswire•5 hours agoArray Presents Data from Cardiovascular Trial with ARRY-797 at the European Society of Cardiology Congress
BOULDER, Colo., Aug. 30, 2016 /PRNewswire/ -- Array BioPharma (ARRY) announced today results from a Phase 2 study of ARRY-797, an oral, selective p38 mitogen-activated protein kinase inhibitor, in patients with lamin A/C-related dilated cardiomyopathy (LMNA-related DCM), a rare, degenerative cardiovascular disease caused by mutations in the LMNA gene and characterized by poor prognosis. The trial results were presented at the European Society of Cardiology Congress 2016 in Rome, Italy. The results demonstrated an absolute mean change from baseline of 69 meters on the six-minute walk test (6MWT) at week 12, the study's primary endpoint (baseline 6MWT ranged from 246 to 412 meters). This magnitude of improvement exceeded historical benchmarks for 6MWT that have served as the basis for recent approvals of other drugs in other rare diseases. ARRY-797 administration also resulted in sustained improvements in N-terminal pro-brain natriuretic peptide (NT-proBNP), functional capacity and cardiac function through 48 weeks in LMNA-related DCM patients.
Array BioPharma Inc. (ARRY)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
|Bid||3.57 x 2700|
|Ask||3.58 x 2400|
|Day's Range||3.55 - 3.75|
|52wk Range||2.38 - 6.01|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-5.46|
|Avg Vol (3m)||2,137,110|
|Dividend & Yield||N/A (N/A)|